

Angioma Alliance 2021 International CCM Scientific Meeting Agenda

Privacy Policy

We would like to reiterate to everyone the "workshop" nature of this very special gathering, and the unique multidisciplinary opportunity to cross germinate ideas and form collaborations. A community of trust and respect for our privacy policy is essential to the success of the CCM Scientific Meeting.

To maintain privacy and encourage presentation and discussion of unpublished data, Angioma Alliance does not publicize written abstracts and **it is not permissible to share the link to the presentation videos or to copy or disseminate unpublished data or results** presented in presentation videos or at the live meeting.

Violations to the privacy policy will be reviewed by the organizing committee and will result in denied Meeting attendance for at least one year.

THURSDAY, NOVEMBER 11

POSTER SESSION 1 - BASIC SCIENCE (presentations will be live) Panel Moderator: Angela Glading & Miguel Lopez-Ramirez

Characterizing Calcium Activity in Krit1 Deficient Endothelial Cells – Nisha Dabni, University of Virginia

Novel Single-Cell Isolation from Cerebral Cavernous Angioma Specimens for Transcriptomic Studies – Ying Li, University of Chicago

Biological Pathways Enriched for Genes Associated with Lesion Burden in Cerebral Cavernous Malformation – Aditya Sriram, UCSF

Zebrafish Models for Cerebral Cavernous Malformation - Claudia Rödel, University of Potsdam

Unravelling CCM Biology Through AI: Identification of New Potential Therapeutic Candidates and Validation Strategy – Andrea Taddei, BenevolentAI

PLENARY

Session I - Pathogenesis & Animal Models

Panel Moderator: Peetra Magnussen and Salim Seyfried

Neuroinflammation Plays a Critical Role in the Pathogenesis of Cerebral Cavernous Malformation Disease – Catherine Chinhchu Lai, UCSD

Evidence for the role of a chromatin remodeler in zebrafish models of cerebral cavernous malformation – Van-Coung Pham, University of Potsdam

Enforced B1-integrin Activation Ameliorates Cerebral Cavernous Malformation (CCM) Lesion Development – Sara McCurdy, UCSD

Session I (continued)

Hypoxia-induced Immunothrombosis and Exacerbation of Cerebral Cavernous Malformation Disease – Eduardo Frias-Anaya, UCSD

Magnetic Resonance and Immunohistochemical Assessment of Lesion Heterogeneity in Chronic Murine Model of Cerebral Cavernous Malformations (CCMs) – Delaney Fisher, University of Virginia

A Murine Model of Acute Hemorrhage in Cerebral and Spinal Cord Cavernomas – Matteo Malinverno, IFOM

Session II - Signaling & Vascular Biology

Panel Moderator: Brent Derry and Mark Kahn

KRIT1 Regulates Neutrophil Adhesion to Fibronectin – Nicholas Nobiletti, University of Rochester

Contribution of Protein-protein Interactions to the Endothelial Barrier Stabilizing Function of the Scaffold Protein KRIT1 – Angela Glading, University of Rochester

Imbalances in the Ephrin B2:EphB4 Ratio Trigger Endothelial Cell Dysfunction and Contributes to CCM Pathogenesis – Julie Sesen, Boston Children's Hospital

The Role of a 20kDa Isoform of Connexin-43 (Cx43-20kDa) in CCM3 – Chelsea Phillips, University of Michigan

The GCKIII Kinases STK24 and STK25 Inhibit Cavernoma Development – Miriam Sartages, Santiago de Compostela

Pdcd10-Stk24/25 Complex Controls Kidney Water Reabsorption by Regulating Aqp2 Membrane Targeting – Xiangjian Zheng, Centenary Institute

FRIDAY, NOVEMBER 12

POSTER SESSION 2 - CLINICAL SCIENCE (presentations will be live) Panel Moderator: Helen Kim and Joseph Zabramski

Rapamycin: What Doses to Test in Mice and Humans - Matthew Hagan, University of Chicago

Mechanistic microRNAs as Diagnostic Biomarkers of Cavernous Angiomas with Symptomatic Hemorrhagic (CASH) – Je Yeong Sone, University of Chicago

A Framework for the Study of Hemorrhagic Microangiopathy with Cerebral Cavernous Malformation as a Paradigm – Sharbel Romanos, University of Chicago

Natural History and Functional Outcome in a Contemporary Cohort of Cerebral Cavernous Malformations – Kelly Flemming, Mayo Clinic

COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation – Abdallah Shkoukani, University of Chicago

PLENARY

Session III - Clinical Genetics & Lesion Development

Panel Moderator: Kelly Flemming and Doug Marchuk

Refined SNP Haplotype Analysis Uncovers a Potential Founder Deletion Mutation in the Cerebral Cavernous Malformation 2 gene – Carol Gallione & Connie Lee, Duke University/Angioma Alliance

Epilepsy Gene Variants Increase Risk of Seizure Onset in Familial Cerebral Cavernous Malformation – Shantel Weinsheimer, UCSF

The Structural Impact of Nonsynonymous Single Nucleotide Polymorphisms in the Dual Cores of CCM2 Phosphotyrosine Binding Domain – Akhil Padarti, TTUHSC El Paso

Impaired Retinoic Acid Signaling in Animal Models of CCM – Nastasja Grdseloff, University of Potsdam

PIK3CA Mutations Synergize with CCM Loss to Fuel Cavernoma Growth – Aileen Ren, University of Pennsylvania

Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations – Mattieu Peyre, Hôpital Pitié-Salpêtrière

Developmental Venous Anomaly: A genetic primer for CCM? – Daniel Snellings, Duke University

Session IV - Biomarkers, Outcome Measures & Clinical Trials

Panel Moderator: Ed Smith and Connie Lee

Multiomic Integration for Biomarker Development in Multiple Contexts of use in Cavernous Angioma Disease – Romuald Girard, University of Chicago

Perfusion and Permeability Imaging as Predictors of Future Cavernous Angioma Hemorrhage and Growth – Je Yeong Sone, University of Chicago

The Cerebral Cavernous Malformations Health Index (CCM-HI): Development and Validation of a Novel Disease-Specific Patient Reported Outcome Measure for Clinical Trials – Jamison Seabury, University of Rochester

The Sycamore Study: Path to a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of REC-994 in CCM – Lisa Boyette, Recursion Pharmaceuticals

Propranolol Treatment for Familial Cerebral Cavernous Malformation: second year-update on the Treat_CCM Trial – Francesca Lazzaroni, IFOM/Treat-CCM

2021 Progress Updates on the Cavernous Angioma with Symptomatic Hemorrhage (CASH) Research Consortium Projects – Issam Awad, University of Chicago